Pfizer takes aim at BMS’ first-in-class Zeposia with FDA nod for ulcerative colitis drug Velsipity aliu Fri, 10/13/2023 – 09:01 More: Pfizer takes aim at BMS' first-in-class Zeposia with FDA nod for ulcerative colitis drug Velsipity Source: fierce
read moreAutomated analysis of language could help diagnose and assess psychiatric conditions More: UCL researchers recommend AI language models for schizophrenia diagnosis Source: News
read moreThe projects will support the development of new and longer-lasting vaccines More: UKRI awards three projects £25m for vaccine development Source: News
read moreBiogen’s Aduhelm headache returns as appeals court revives part of investor lawsuit esagonowsky Thu, 10/12/2023 – 15:14 More: Biogen's Aduhelm headache returns as appeals court revives part of investor lawsuit Source: fierce
read moreAfter Novo’s Ozempic logs victory in kidney disease trial, dialysis heavyweight DaVita raises doubts fkansteiner Thu, 10/12/2023 – 14:53 More: After Novo's Ozempic logs victory in kidney disease trial, dialysis heavyweight DaVita raises doubts Source: fierce
read moreIncyte taps actor to help tell the stories of eczema patients, with focus on teen’s Opzelura experience ntaylor Thu, 10/12/2023 – 11:14 More: Incyte taps actor to help tell the stories of eczema patients, with focus on teen’s Opzelura experience
read more© 1994 - 2026 B.M. Pharmaceuticals